Welcome to our dedicated page for Integra LifeSciences Holdings news (Ticker: IART), a resource for investors and traders seeking the latest updates and insights on Integra LifeSciences Holdings stock.
Integra LifeSciences Holdings Corporation (NASDAQ: IART) is a global leader in medical technology, headquartered in Plainsboro, New Jersey. Established in 1989, Integra is dedicated to reducing uncertainty for surgeons, allowing them to focus on providing outstanding patient care. The company offers innovative solutions in various medical fields including orthopedic extremity surgery, neurosurgery, spine surgery, and reconstructive and general surgery.
Integra's diverse portfolio includes products for regenerative therapy, extremity orthopedics, and neurosurgical applications. Their orthopedic product line features devices and implants for spine, foot and ankle, hand and wrist, shoulder and elbow, tendon and peripheral nerve protection and repair, and wound repair. The company is also a key player in the neurosurgery market, offering a broad range of implants, devices, instruments, and systems used in neurosurgery, neuromonitoring, neurotrauma, and critical care.
Integra operates through two main segments: Codman Specialty Surgical and Tissue Technologies. The Codman Specialty Surgical segment generates the majority of the company's revenue, focusing on neurosurgical and surgical instrumentation. The Tissue Technologies segment covers regenerative and advanced wound care products.
With over 3,500 employees worldwide, Integra serves markets in Europe, the Asia-Pacific region, and other parts of the globe, although the bulk of its revenue comes from domestic sales. Recently, the company announced its second-quarter 2023 financial results, highlighting a total revenue of $381.3 million, a slight decline compared to the previous year, primarily due to a recall issue at their Boston manufacturing facility. Despite this, the company showed resilience with strong performances in certain product lines and updated their guidance for 2023 revenue and earnings per share.
Integra's recent acquisition of Acclarent, a leader in ENT procedures, for $275 million, showcases their ongoing commitment to expanding their product offerings and improving healthcare outcomes. This acquisition is expected to close by the second quarter of 2024 and will significantly bolster Integra's position in the ENT market.
Integra continues to develop and launch groundbreaking products such as the CereLink ICP Monitoring System for intracranial pressure monitoring and the MicroMatrix Flex, which addresses complex wound reconstruction needs. These innovations reflect Integra's dedication to advancing surgical, neurologic, and regenerative care standards.
For the latest updates and further information, visit www.integralife.com.
Integra LifeSciences Holdings (NASDAQ: IART), a leading global medical technology company, has announced it will release its second quarter 2024 financial results on Monday, July 29, 2024, before the market opens. The company's management team will host a conference call at 8:30 a.m. ET on the same day to discuss the results.
A live webcast of the conference call will be available on the Investors section of Integra's website at investor.integralife.com. Interested participants can register to receive dial-in details and an individual pin for the call. Integra recommends joining the call 10 minutes before it starts. A webcast replay will be available on the company's Investors section following the call.
Integra LifeSciences Holdings (NASDAQ: IART), a prominent medical technology company, announced that its CFO, Lea Knight, will present at the 2024 Bank of America Healthcare Conference on May 14, 2024, at 4:40pm ET. The presentation will be livestreamed on the company's investor relations website.
Integra LifeSciences Holdings reported first quarter 2024 financial results, with revenues of $368.9 million declining 3.1% on a reported basis and 2.5% on an organic basis compared to the prior year. GAAP earnings per share were $(0.04), while adjusted earnings per share were $0.55. The company completed the acquisition of Acclarent, Inc., updating full-year revenue guidance to a range of $1.672 billion to $1.687 billion.
Integra LifeSciences will showcase the CereLink® Intracranial Pressure (ICP) Monitoring System at the AANS Annual Scientific Meeting. The system offers advanced continuous ICP monitoring with minimal drift, MR conditional capability, durable sensors, and advanced data features. The relaunch addresses the important need for accurate ICP monitoring in managing brain injuries, strokes, and other conditions, demonstrating Integra's commitment to innovation and patient care.
FAQ
What is the current stock price of Integra LifeSciences Holdings (IART)?
What is the market cap of Integra LifeSciences Holdings (IART)?
What does Integra LifeSciences Holdings Corp. specialize in?
Where is Integra LifeSciences headquartered?
What are the primary segments of Integra LifeSciences?
What recent acquisition was announced by Integra LifeSciences?
What are some of the key products offered by Integra LifeSciences?
How did Integra perform financially in the second quarter of 2023?
What is the purpose of Integra’s CereLink ICP Monitoring System?
How many employees does Integra LifeSciences have?
Which markets does Integra LifeSciences serve?
What is Integra’s strategy for growth in 2024?
